Notes

(C) 2008 Elsevier, whose permission to mount this version for private study and research is acknowledged.  The repository version is the author's final draft.

 

References

1. Wells, D.J., Wells, K.E., Asante, E.A., Turner, G., Sunada, Y., Campbell, K.P.,
Walsh, F.S. and Dickson, G. (1995) Expression of human full-length and
minidystrophin in transgenic mdx mice: implications for gene therapy of
Duchenne muscular dystrophy. Hum Mol Genet, 4, 1245-50.

2. Neri, M., Torelli, S., Brown, S., Ugo, I., Sabatelli, P., Merlini, L., Spitali, P.,
Rimessi, P., Gualandi, F., Sewry, C. et al. (2007) Dystrophin levels as low as 30%
are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord, 17,
913-8.

3. Athanasopoulos, T., Graham, I.R., Foster, H. and Dickson, G. (2004)
Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for
Duchenne muscular dystrophy (DMD). Gene Ther, 11 Suppl 1, S109-21.

4. Fabb, S.A., Wells, D.J., Serpente, P. and Dickson, G. (2002) Adeno-associated
virus vector gene transfer and sarcolemmal expression of a 144 kDa microdystrophin
effectively restores the dystrophin-associated protein complex and
inhibits myofibre degeneration in nude/mdx mice. Hum Mol Genet, 11, 733-41.

5. Gregorevic, P., Allen, J.M., Minami, E., Blankinship, M.J., Haraguchi, M., Meuse,
L., Finn, E., Adams, M.E., Froehner, S.C., Murry, C.E. et al. (2006) rAAV6-
microdystrophin preserves muscle function and extends lifespan in severely
dystrophic mice. Nat Med, 12, 787-9.

6. Gregorevic, P., Blankinship, M.J., Allen, J.M. and Chamberlain, J.S. (2008)
Systemic microdystrophin gene delivery improves skeletal muscle structure and
function in old dystrophic mdx mice. Mol Ther, 16, 657-64.

7. Gregorevic, P., Blankinship, M.J., Allen, J.M., Crawford, R.W., Meuse, L., Miller,
D.G., Russell, D.W. and Chamberlain, J.S. (2004) Systemic delivery of genes to
striated muscles using adeno-associated viral vectors. Nat Med, 10, 828-34.

8. Harper, S.Q., Hauser, M.A., DelloRusso, C., Duan, D., Crawford, R.W., Phelps,
S.F., Harper, H.A., Robinson, A.S., Engelhardt, J.F., Brooks, S.V. et al. (2002)
Modular flexibility of dystrophin: implications for gene therapy of Duchenne
muscular dystrophy. Nat Med, 8, 253-61.

9. Watchko, J., O'Day, T., Wang, B., Zhou, L., Tang, Y., Li, J. and Xiao, X. (2002)
Adeno-associated virus vector-mediated minidystrophin gene therapy improves
dystrophic muscle contractile function in mdx mice. Hum Gene Ther, 13, 1451-60.

10. Banks, G.B., Gregorevic, P., Allen, J.M., Finn, E.E. and Chamberlain, J.S. (2007)
Functional capacity of dystrophins carrying deletions in the N-terminal actinbinding
domain. Hum Mol Genet, 16, 2105-13.

11. Liu, M., Yue, Y., Harper, S.Q., Grange, R.W., Chamberlain, J.S. and Duan, D.
(2005) Adeno-associated virus-mediated microdystrophin expression protects
young mdx muscle from contraction-induced injury. Mol Ther, 11, 245-56.

12. Nakai, H., Fuess, S., Storm, T.A., Muramatsu, S., Nara, Y. and Kay, M.A. (2005)
Unrestricted hepatocyte transduction with adeno-associated virus serotype 8
vectors in mice. J Virol, 79, 214-24.

13. Garmory, H.S., Brown, K.A. and Titball, R.W. (2003) DNA vaccines: improving
expression of antigens. Genet Vaccines Ther, 1, 2.

14. Kozak, M. (2005) Regulation of translation via mRNA structure in prokaryotes and
eukaryotes. Gene, 361, 13-37.

15. Koldej, R., Cmielewski, P., Stocker, A., Parsons, D.W. and Anson, D.S. (2005)
Optimisation of a multipartite human immunodeficiency virus based vector
system; control of virus infectivity and large-scale production. J Gene Med, 7,
1390-9.

16. Michel, M., Lone, Y.C., Centlivre, M., Roux, P., Wain-Hobson, S. and Sala, M.
(2007) Optimisation of secretion of recombinant HBsAg virus-like particles:
Impact on the development of HIV-1/HBV bivalent vaccines. Vaccine, 25, 1901-
11.

17. Murray, E.L. and Schoenberg, D.R. (2007) A+U-rich instability elements
differentially activate 5'-3' and 3'-5' mRNA decay. Mol Cell Biol, 27, 2791-9.

18. Bennicelli, J., Wright, J.F., Komaromy, A., Jacobs, J.B., Hauck, B., Zelenaia, O.,
Mingozzi, F., Hui, D., Chung, D., Rex, T.S. et al. (2008) Reversal of blindness in
animal models of leber congenital amaurosis using optimized AAV2-mediated
gene transfer. Mol Ther, 16, 458-65.

19. Radcliffe, P.A., Sion, C.J., Wilkes, F.J., Custard, E.J., Beard, G.L., Kingsman,
S.M. and Mitrophanous, K.A. (2008) Analysis of factor VIII mediated suppression
of lentiviral vector titres. Gene Ther, 15, 289-97.

20. Gao, G., Vandenberghe, L.H., Alvira, M.R., Lu, Y., Calcedo, R., Zhou, X. and
Wilson, J.M. (2004) Clades of Adeno-associated viruses are widely disseminated
in human tissues. J Virol, 78, 6381-8.

21. Gao, G., Vandenberghe, L.H. and Wilson, J.M. (2005) New recombinant
serotypes of AAV vectors. Curr Gene Ther, 5, 285-97.

22. Gao, G.P., Alvira, M.R., Wang, L., Calcedo, R., Johnston, J. and Wilson, J.M.
(2002) Novel adeno-associated viruses from rhesus monkeys as vectors for
human gene therapy. Proc Natl Acad Sci U S A, 99, 11854-9.

23. Inagaki, K., Fuess, S., Storm, T.A., Gibson, G.A., McTiernan, C.F., Kay, M.A. and
Nakai, H. (2006) Robust systemic transduction with AAV9 vectors in mice:
efficient global cardiac gene transfer superior to that of AAV8. Mol Ther, 14, 45-
53.

24. Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., Chen, C., Li, J. and
Xiao, X. (2005) Adeno-associated virus serotype 8 efficiently delivers genes to
muscle and heart. Nat Biotechnol, 23, 321-8.

25. Townsend, D., Yasuda, S., Li, S., Chamberlain, J.S. and Metzger, J.M. (2008)
Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal
muscle. Mol Ther, 16, 832-5.

26. Zincarelli, C., Soltys, S., Rengo, G. and Rabinowitz, J.E. (2008) Analysis of AAV
serotypes 1-9 mediated gene expression and tropism in mice after systemic
injection. Mol Ther, 16, 1073-80.

27. Yoshimura, M., Sakamoto, M., Ikemoto, M., Mochizuki, Y., Yuasa, K., Miyagoe-
Suzuki, Y. and Takeda, S. (2004) AAV vector-mediated microdystrophin
expression in a relatively small percentage of mdx myofibers improved the mdx
phenotype. Mol Ther, 10, 821-8.

28. Judge, L.M., Haraguchiln, M. and Chamberlain, J.S. (2006) Dissecting the
signaling and mechanical functions of the dystrophin-glycoprotein complex. J Cell
Sci, 119, 1537-46.

29. Phelps, S.F., Hauser, M.A., Cole, N.M., Rafael, J.A., Hinkle, R.T., Faulkner, J.A.
and Chamberlain, J.S. (1995) Expression of full-length and truncated dystrophin
mini-genes in transgenic mdx mice. Hum Mol Genet, 4, 1251-8.

30. Warner, L.E., DelloRusso, C., Crawford, R.W., Rybakova, I.N., Patel, J.R.,
Ervasti, J.M. and Chamberlain, J.S. (2002) Expression of Dp260 in muscle
tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially
prevents dystrophy. Hum Mol Genet, 11, 1095-105.

31. Corrado, K., Rafael, J.A., Mills, P.L., Cole, N.M., Faulkner, J.A., Wang, K. and
Chamberlain, J.S. (1996) Transgenic mdx mice expressing dystrophin with a
deletion in the actin-binding domain display a "mild Becker" phenotype. J Cell
Biol, 134, 873-84.

32. Yue, Y. and Dongsheng, D. (2002) Development of multiple cloning site cisvectors
for recombinant adeno-associated virus production. Biotechniques, 33,
672, 674, 676-8.

33. Li, X., Eastman, E.M., Schwartz, R.J. and Draghia-Akli, R. (1999) Synthetic
muscle promoters: activities exceeding naturally occurring regulatory sequences.
Nat Biotechnol, 17, 241-5.

34. Liu, Y.L., Wagner, K., Robinson, N., Sabatino, D., Margaritis, P., Xiao, W. and
Herzog, R.W. (2003) Optimized production of high-titer recombinant adenoassociated
virus in roller bottles. Biotechniques, 34, 184-9.